Bausch Health Study Estimates 62% One-Year Survival in Severe Alcohol-Associated Hepatitis Patients

By Public Technologies
  • Bausch Health’s Salix will present severe alcohol-associated hepatitis research at The Liver Meeting Nov. 5-9, 2026, in Denver.
  • The study of 1,630 U.S. adults found substantial mortality and rehospitalization, highlighting the need for better disease management and effective therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202611060700CANADANWCANADAPR_C8071) on November 06, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk